Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Sponsor: Henan Cancer Hospital
Terminated
Investigators' decision
Other terminated trials from Henan Cancer Hospital
Other Metastatic Breast Cancer trials with similar outcome
This PHASE1/PHASE2 trial investigates Metastatic Breast Cancer and is currently terminated or withdrawn. Henan Cancer Hospital leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Jan 2025 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jan 2022 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henan Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .